Paul Ashton

Company: Inflammasome Therapeutics, Inc.

Job title: President & CEO

Seminars:

Retinal Disease & Inflammasome Activation 12:30 pm

Inflammasome activation is a key pathway in macular degeneration Blocking inflammasome activation prevents macular degeneration in vivo Clinical data supports efficacy of this strategyRead more

day: Day 2 - Track B - Morning

SWOT Analysis-Style Panel Discussion – Topics to be Addressed: 9:30 am

Reviewing the inflammasome therapeutics landscape – what have we learnt from recent progress and failures? What are the strengths of inflammasome therapeutics that continue to drive their development in pharma and biotech pipelines? What is the market opportunity and untapped clinical areas versus greatest unmet patient clinical need that can be addressed by emerging inflammasome…Read more

day: Day One